Testosterone Protocol Renaissance: Why HIMS Pivots From GLP-1

Why Telehealth Is Rotating Into Testosterone

The GLP-1 gold rush has created market saturation. Obesity treatment is competitive, margins are compressed, and patient acquisition costs for semaglutide/tirzepatide are stratospheric. HIMS's pivot toward testosterone optimization makes mechanistic sense: testosterone deficiency affects 40% of men over 40, diagnostic barriers remain high in traditional medicine, and the protocol is straightforward to monitor via bloodwork.

But here's what matters clinically: telehealth testosterone programs only work if they're built on solid lab protocols. Too many programs treat testosterone as a simple binary—"low" or "normal"—without understanding the downstream hormonal cascade.

The Testosterone Axis: What You Actually Need to Test

Testosterone exists in three forms:

Total testosterone (200-900 ng/dL reference range): Measures all circulating testosterone, bound and free. Useful screening tool but incomplete picture.

Free testosterone (<2% of total): The bioavailable fraction that binds to androgen receptors in muscle, bone, liver, and brain. This is what matters clinically. Reference ranges are typically 50-210 pg/mL, but optimization sits closer to 150-180 pg/mL for most men seeking performance and recovery.

Albumin-bound testosterone: The intermediate form, relevant in edge cases but rarely tested.

Any responsible telehealth program must order all three. Total testosterone alone misses the SHBG story—sex hormone binding globulin, the carrier protein that shuttles testosterone and estradiol. High SHBG (common in endurance athletes, certain genetic polymorphisms) leaves you testosterone-depleted despite "normal" total levels.

Critical Baseline Testing Before Protocol Initiation

Before any testosterone therapy, establish baseline:

• Testosterone panel: total, free, SHBG
• Estradiol (sensitive LC-MS, not immunoassay): Males typically run 20-30 pg/mL. Exogenous testosterone can aromatize to estradiol; you need the real number to know if aromatase inhibitors (AI) are warranted. Reference ranges are useless here—optimization is the goal.
• Hematocrit/hemoglobin: Testosterone increases RBC production. Baseline establishes whether you can safely tolerate 12-18% hematocrit elevation.
• Lipid panel (fasting): Testosterone can shift HDL/LDL ratios, especially at higher doses.
• Liver function (AST, ALT, GGT): Parenteral testosterone is hepatic-neutral, but oral testosterone (methyltestosterone) is hepatotoxic. Transdermal/topical/injection are preferred.
• PSA (prostate-specific antigen): Mandatory. Controversial in literature, but risk stratification requires baseline. Any rise >1 ng/mL year-over-year signals need for urologic review.
• Thyroid panel (TSH, Free T4, Free T3): Testosterone modulates thyroid hormone metabolism. Hypothyroidism blunts testosterone response.
• Cortisol (morning, fasting): Elevated cortisol suppresses LH/FSH, tanking testosterone. If cortisol >20 µg/dL, address that first (stress, sleep, ashwagandha, phosphatidylserine).

Synergistic Supplementation With Testosterone Optimization

If you're pursuing testosterone therapy through telehealth, the protocol is incomplete without supporting compounds:

Magnesium glycinate (400-500 mg/day, evening): Cofactor for DHEA synthesis and cortisol regulation. Glycinate form avoids GI effects. Test baseline magnesium (most labs only show serum, which is unreliable; ask for RBC magnesium).

Zinc (25-30 mg/day, with food): Essential for LH synthesis and androgen receptor expression. Excess zinc (>50 mg/day chronically) impairs copper absorption and immunity. Pair with copper (2-3 mg/day) if supplementing long-term.

Vitamin D3/K2 (4,000-5,000 IU D3 + 200-360 µg K2 MK-7): Vitamin D receptor polymorphisms affect testosterone sensitivity. K2 drives calcium into bone, away from soft tissues. Test 25-OH vitamin D; optimal is 50-70 ng/mL, not the reference range floor of 20 ng/mL.

Creatine monohydrate (5 g/day): Increases intramuscular ATP and DHT production. Responders see 2–3 kg lean mass gains over 8 weeks. Requires adequate water intake.

NAC (600-1,200 mg/day): Glutathione precursor. Supports liver conjugation of excess estradiol from aromatization. Beneficial if you're on testosterone + concerned about gynecomastia risk.

Omega-3 (2-3 g EPA+DHA/day): Anti-inflammatory, supports cardiovascular health during testosterone therapy (which can increase blood pressure transiently).

Collagen peptides (10-20 g/day): Synergizes with testosterone to rebuild tendon/ligament tissue. Take with vitamin C for hydroxylation.

Ashwagandha (KSM-66 extract) (500-600 mg/day, divided): Reduces cortisol by 25-30% in clinical trials. Frees up more bioavailable testosterone by suppressing SHBG slightly. Works best at 8-12 week mark.

Monitoring Cadence and Dose Titration

Responsible telehealth programs check labs at:

• Week 4: Verify absorption, early side-effect detection (hematocrit creep, lipid shift).
• Week 8: Full panel (testosterone, free testosterone, estradiol, hematocrit, liver function).
• Month 3, then every 6 months: Steady-state assessment.

Dose typically starts 75–100 mg/week (transdermal) or 200–250 mg/week (intramuscular). Titrate in 25–50 mg/week increments based on free testosterone response, not total testosterone.

The goal is free testosterone 150-200 pg/mL, not 800 ng/dL total testosterone. The latter creates aromatization risk, cardiovascular stress, and diminishing returns on muscle/recovery gains.

The Bottom Line

Telehealth's pivot into testosterone is smart market positioning, but execution matters enormously. A protocol that orders only total testosterone and skips baseline PSA/estradiol/hematocrit is malpractice by another name. SHBG, free testosterone, and estradiol must anchor every program. Supplemental support—magnesium, zinc, vitamin D3, NAC, ashwagandha—amplifies response and reduces side-effect risk. Most critically: baseline labs, 8-week recheck labs, and ongoing monitoring separate a medical program from a marketing operation.

The crowding in GLP-1 space may push HIMS toward testosterone, but the clinical opportunity exists only if they execute the endocrinology correctly.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.